Previous studies have investigated the consequences of ADI in conjunction with gefitinib on the growth and apoptosis of NSCLC drug-resistant cell lines, exploring its role in reversing EGFR-TKI resistance [28, 29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.